CEL-SCI gets FDA approval to move forward with Multikine study

CEL-SCI announced an outcome from its recent meeting with the FDA regarding the path to approval for its first-line investigational cancer immunotherapy Multikine. Based on strong safety and efficacy data from CEL-SCI’s completed Phase 3 head and neck cancer study, the FDA indicated CEL-SCI may move forward with a confirmatory Registration Study of Multikine in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression.